Navigation Links
Simcere Pharmaceutical Group to Announce Third Quarter 2008 Earnings on Thursday, November 6, 2008
Date:10/21/2008

NANJING, China, Oct. 21 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and innovative anti-cancer pharmaceuticals in the rapidly growing China market, announced today that it intends to release its 2008 third quarter results on Thursday, November 6, 2008, before the market opens in the United States. Simcere's chief executive officer, Jinsheng Ren, and chief financial officer, Frank Zhigang Zhao, will host an earnings conference call to discuss the company's 2008 third quarter results on Thursday, November 6, at 8 a.m. ET (Thursday, November 6, at 9 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:

United States toll-free dial-in number: +1-866-314-4483

United States toll / International dial-in number: +1-617-213-8049

China toll-free dial-in number: 10-800-130-0399

Hong Kong dial-in number: +852-3002-1672

Please ask to be connected to Simcere's Q3 2008 Earnings Call and provide the following passcode: 91351092. Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's Web site at http://www.simcere.com .

Following the earnings conference call, an archive of the call will be available by dialing:

United States toll-free dial-in number: +1-888-286-8010

United States toll / International dial-in number: +1-617-801-6888

The passcode for replay participants is: 53343092. The telephone replay also will be archived on the "I
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Simcere Pharmaceutical Group to Announce Third Quarter 2007 Earnings on Monday, November 5, 2007
2. Simcere Pharmaceutical Group Announces the Appointment of New Vice President of Marketing and Two Senior Promotions
3. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
4. Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip
5. Simcere Pharmaceutical Group to Participate in Upcoming Investor Conferences in New York
6. Simcere Pharmaceutical Group to Announce Second Quarter 2008 Earnings on Tuesday, August 5, 2008
7. Simcere Pharmaceutical Group Announces Two Senior Promotions and Appointment of New Vice President of Human Resources
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... May 24, 2013 Vestiage, Inc. ... company focused on science-based research and development, sales ... cosmeceuticals and nutraceuticals, announced today that it is ... for the sale of Reluma Skin Illuminating Facial ... and application by sending an email to info(at)vestiageinc(dot)com ...
(Date:5/23/2013)... Every day, their baby stopped breathing, his collapsed bronchus ... April and Bryan Gionfriddo watched helplessly, just praying that ... few doctors said he had a good chance of ... her now 20-month-old son, Kaiba. "At that point, we ... it and run with it." , They found hope ...
(Date:5/23/2013)... 23, 2013 Can economic incentives such ... motivate members of the public to increase their donations ... Johns Hopkins Carey Business School Assistant Professor Mario ... to a large body of recent research that supports ... 24, 2013, issue of Science that the World Health ...
(Date:5/23/2013)... May 23, 2013 PuraMed BioScience ® ... marketer of over-the-counter (OTC) medicinal and healthcare products, ... on the company based on low market capitalization ... Non-Prescription, All Natural Product to Treat Migraine Headaches ... #1 Prescription Competitor , Currently Available Nationwide ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3
... This release is available in French . Physicists ... energy involved in adding electrons to semi-conductor nanocrystals, also known ... and other areas of science. Dr. Peter Grtter, McGill,s Associate ... that his research team has developed a cantilever force sensor ...
... EDMONTON , May 11 ... company focused on developing medical device,products for use ... it has,received regulatory concurrence from the United States ... product, Occlusin(R) 500 Artificial,Embolization Device (OCL 500) in ...
... ORLANDO, Fla. , May 11 GeneLink, Inc. (OTC Bulletin ... quarter ended March 31, 2010 . , , ... , , , ... Quarterly operating loss reduced by 14% over Q4 2009 Comparable quarter gross profit improvement ...
Cached Biology Technology:Quantum move toward next generation computing 2IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S. 2IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S. 3GeneLink Reports First Quarter Gains 2
(Date:5/24/2013)... disease, scientists have focused among other factors on ... it is the accumulation of A-beta that causes the known ... the formation of A-beta is APP. Alessia Soldano and Bassem ... of APPL the fruit-fly version of APP in ... (VIB/KU Leuven): "We have discovered that APPL ensures that brain ...
(Date:5/23/2013)... Automated conserved noncoding sequence (CNS) discovery reveals differences ... , Within the genome of each species, there are ... in position and sequence over millions of years, but ... evolutionarily stable sequences, so-called conserved noncoding sequences (CNSs), are ... the condensation of chromosomes, but the function of many ...
(Date:5/23/2013)... honored more than 165 staff for their creation, ... annual Intellectual Property Commercialization Recognition & Rewards Program ... laboratory named materials scientist Jun Liu Inventor of ... that can store large amounts of energy, ease ... time it takes to charge cell phones, electric ...
Breaking Biology News(10 mins):A new strategy required in the search for Alzheimer's drugs? 2Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
... available in German . Plants, algae, and ... solar energy because they are able to almost completely transform ... the electrons set free by the photons are transported out ... driving force for chemical reactions. Japanese researchers have now developed ...
... Researchers from Nano-Science Center, University of Copenhagen and ... a general method to study membrane proteins. This ... proteins, and it will reduce the way from ... pharmaceutical industry is interested and participate in a ...
... have been selected for awards from the Merck/AAAS ... Institute for Science Education (MISE) and the American ... program awards provide up to $60,000, paid over ... chemistry departments at the recipient institution. This ...
Cached Biology News:Plugging in molecular wires 2Major step for drug discovery and diagnostics 2
... and antibody-based immunoaffinity matrices, such as ... times without compromising antigen-antibody reactivity, the ... agents has precluded the application of ... The CHEMICON Re-Blot Plus Western Blot ...
Applications: Western blotting ...
Applications: Western blotting ...
...
Biology Products: